G1 Therapeutics is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes small molecule therapies for cancer treatment. Its product COSELA reduces chemotherapy-induced myelosuppression in adult patients when administered before specific chemotherapy regimens. G1 Therapeutics is also developing trilaciclib and lerociclib, oral CDK4/6 inhibitors, and rintodestrant, an oral selective estrogen receptor degrader, for multiple oncology indications.